EP3560516A1 — Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
Assigned to Vestlandets Innovasjonsselskap AS · Expires 2019-10-30 · 7y expired
What this patent protects
The present invention relates in a first aspect to a pharmaceutical composition comprising beta-sitosterol or a homolog thereof in combination with a BRAF inhibitor and/or a MEK inhibitor and/or an ERK inhibitor. In particular, the present invention relates to a combination of th…
USPTO Abstract
The present invention relates in a first aspect to a pharmaceutical composition comprising beta-sitosterol or a homolog thereof in combination with a BRAF inhibitor and/or a MEK inhibitor and/or an ERK inhibitor. In particular, the present invention relates to a combination of the beta-sitosterol in combination with a BRAF inhibitor like vemurafenib, PLX4720 or dabrafenib or the MEK inhibitor trametinib. The composition is particularly useful in the treatment of cancer including metastatic cancer for example by oral or intravenous administration of both. The beta-sitosterol and the at least one of the BRAF inhibitor and/or MEK inhibitor and/or an ERK inhibitor being administered simultaneously, separately or sequentially. In a further aspect, a method of treating individuals suffering from cancer using the pharmaceutical composition according to the present invention is disclosed.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.